Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
Rheumatology (Oxford, England)|September 13, 2014
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortJames Bluett, Catharine Morgan, Layla Thurston, et al.
Chembiochem : a European Journal of Chemical Biology|June 6, 2017
Traceless Cleavage of Protein-Biotin Conjugates under Biologically Compatible ConditionsJoseph Cowell, Matthew Buck, Ali H Essa, et al.
Arthritis Research & Therapy|October 9, 2012
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortDarren Plant, Ibrahim Ibrahim, Mark Lunt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Pim Kinases as Therapeutic Targets in Early Rheumatoid ArthritisNicola J Maney, Henrique Lemos, Ben Barron-Millar, et al.
Rheumatology (Oxford, England)|August 25, 2023
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseasesPeter C Taylor, Ernest Choy, Xenofon Baraliakos, et al.
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Plos One|January 12, 2012
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapyDawn L Cooper, Stephen G Martin, James I Robinson, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathwaysCatherine Potter, Heather J Cordell, Anne Barton, et al.
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
Pageof 22